Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?

Article

Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?

Frédéric Cortes,Florence Portet,J. Touchon,B. Vellas-2007-10-09-PubMed

21

TL;DRAbstract

Changes in AD in patients under AChEI treatment are not sufficient to demonstrate the effect of a new treatment at 6 months. However, 18-month trials appear to have the potential to demonstrate clearly the effect of a new drug.

Chat with Paper

AI Agents for this Paper

Changes in AD in patients under AChEI treatment are not sufficient to demonstrate the effect of a new treatment at 6 months. However, 18-month trials appear to have the potential to demonstrate clearly the effect of a new drug.

Keywords

MedicineInternal medicineAcetylcholinesteraseClinical trialDiseaseCohortAlzheimer's diseaseRivastigmine

Chat

Click to start Chat